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Association of Canine Osteosarcoma and Monocyte Phenotype and
Chemotactic Function
J.L. Tuohy, B.D.X. Lascelles, E.H. Griffith, and J.E. Fogle
Background: Monocytes/macrophages are likely key cells in immune modulation in dogs with osteosarcoma (OSA).
Increased peripheral monocyte counts are negatively correlated with shorter disease-free intervals in dogs with OSA. Under-
standing the monocyte/macrophage’s modulatory role in dogs with OSA can direct further studies in immunotherapy devel-
opment for OSA.
Hypothesis/Objectives: That OSA evades the immune response by down-regulating monocyte chemokine receptor expres-
sion and migratory function, and suppresses host immune responses.
Animals: Eighteen dogs with OSA that have not received definitive treatment and 14 healthy age-matched controls
Methods: Clinical study—expression of peripheral blood monocyte cell surface receptors, monocyte mRNA expression
and cytokine secretion, monocyte chemotaxis, and survival were compared between clinical dogs with OSA and healthy con-
trol dogs.
Results: Cell surface expression of multiple chemokine receptors is significantly down-regulated in peripheral blood mono-
cytes of dogs with OSA. The percentage expression of CCR2 (median 58%, range 2–94%) and CXCR2 expression (median
54%, range 2–92%) was higher in control dogs compared to dogs with OSA (CCR2 median 29%, range 3–45%, P = 0.0006;
CXCR2 median 23%, range 0.2–52%, P = 0.0007). Prostaglandin E2 (PGE2) (OSA, median 347.36 pg/mL, range 103.4–
1268.5; control, 136.23 pg/mL, range 69.93–542.6, P = .04) and tumor necrosis factor-alpha (TNF-a) (P = .02) levels are
increased in OSA monocyte culture supernatants compared to controls. Peripheral blood monocytes of dogs with OSA exhi-
bit decreased chemotactic function when compared to control dogs (OSA, median 1.2 directed to random migration, range
0.8–1.25; control, 1.6, range of 0.9–1.8, P = .018).
Conclusions and Clinical Importance: Dogs with OSA have decreased monocyte chemokine receptor expression and mono-
cyte chemotaxis, potential mechanisms by which OSA might evade the immune response. Reversal of monocyte dysfunction
using immunotherapy could improve survival in dogs with OSA.
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Appendicular osteosarcoma (OSA), the most com-mon primary bone malignancy in dogs, has a high
rate of metastasis and a poor prognosis.1,2 The overall
median survival time from time of diagnosis for dogs
that receive standard-of-care therapy (primary tumor
removal and adjuvant chemotherapy) is approximately
10–12 months, with a 20% 2-year survival rate.1 Metas-
tasis is the primary cause of death in dogs with OSA,
with approximately 90% of dogs already harboring
occult metastatic disease at diagnosis.1 Controlling meta-
static disease is crucial to improving outcomes in OSA.
Tumor-induced immune suppression is one of the
mechanisms by which malignancies ensure survival. For
example, tumors recruit monocytes and macrophages
and induce pro-tumorigenic changes in their phenotypes
and function leading to a microenvironment that favors
tumor growth.3 OSA cells from dogs secrete Transform-
ing Growth Factor-beta (TGF-b), which likely
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contributes to immune suppression as TGF-b is consid-
ered an inhibitory immunoregulatory cytokine.4–6 Inter-
estingly, dogs with OSA who develop infections after
limb-spare surgery have been observed to almost double
their median survival time, potentially via up-regulation
of antitumor immunity.7 Dogs with OSA and infections
were half as likely to die, half as likely to develop
metastasis, and these survival effects were because of a
delay in metastasis rather than control of local tumor
recurrence.7 Studies in mice have confirmed these
observations and suggest that the antitumor effects of
infection could be modulated via monocytes and macro-
phages. Mice with chronic osteomyelitis that developed
OSA experienced improved survival, had increased
numbers of inflammatory monocytes, and depletion of
monocytes/macrophages in these mice reversed the sur-
vival benefit afforded by osteomyelitis.8 Understanding
the role of immunomodulatory cells such as monocytes
in creating a protumorigenic environment in dogs with
OSA will inform future investigations to identify thera-
peutic targets to reverse tumor-induced immune dys-
function and inhibit metastatic disease. To this end, we
sought to identify phenotypic and functional differences
in monocytes between dogs with OSA and healthy dogs.
The objectives of our study were (1) to compare cell
surface receptor expression between monocytes from
OSA and healthy dogs, (2) to compare mRNA expres-
sion and cytokine secretion between monocytes from
OSA and healthy dogs, (3) to compare chemotactic dif-
ferences between monocytes from OSA and healthy
dogs, and (4) to analyze associations between OSA sur-
vival and peripheral blood monocyte counts/receptor
expression. Our hypothesis was that OSA evades the
immune response by down-regulating monocyte chemo-
kine receptor expression and migratory function, and
suppresses host immune responses.
Materials and Methods
Patient Enrollment and Sample Collection
Client-owned dogs diagnosed with OSA that had not received
any tumor-directed therapy or immunomodulatory drugs were
enrolled into the study. Because of the enrollment of dogs at a ter-
tiary referral center, some dogs with OSA had been prescribed
anti-inflammatory medications by their primary referring veteri-
narian. A similar population of age-matched medium and large-
breed control dogs without known disease that were also not
receiving any anti-inflammatory or immunomodulatory medica-
tions were recruited for the study by the North Carolina State
University (NCSU) Clinical Studies Core. Verbal and written
owner consent were obtained for all dogs participating in the
study, and peripheral blood samples were collected under an
approved Institutional Animal Care and Use Committee (IACUC)
protocol.
Isolation of Peripheral Blood Mononuclear Cells
(PBMCs) and of a Purified Monocyte Population
Approximately 25 mL of peripheral blood was collected into
EDTA blood collection tubes from 14 control dogs and 18 dogs
with OSA via venipuncture. Five mL blood was submitted for
complete blood counts (CBC) in 10 healthy controls and 18 dogs
with OSA. Peripheral blood mononuclear cells (PBMCs) were
isolated by density gradient centrifugation using Histopaque-
1077.a A portion of the PBMCs from 13 healthy controls and 18
dogs with OSA was preserved for cell surface staining, and a por-
tion underwent cell sorting to isolate a purified monocyte popula-
tion using a MoFlo high-speed cell sorter.b Monocyte cell
isolation was performed based on forward (FSC) versus side scat-
ter (SSC), and CD14+ expression, and the phenotype of the sorted
monocytes was confirmed via light microscopy.9 Approximately
1 9 106 sorted monocytes from 7 healthy controls and 7 dogs with
OSA were centrifuged and resuspended in RNAprotectc cell
reagent for PCR analysis. Sorted monocytes from 8 healthy con-
trols and 7 dogs with OSA were used for stimulation cultures, and
sorted monocytes from 14 healthy controls and 5 dogs with OSA
were used for chemotaxis assays, as outlined below.
Flow Cytometry (FACS) Analysis
A portion of the PBMCs from 13 healthy controls and 18 dogs
with OSA were centrifuged, resuspended in 2 mL Phosphate-
Buffered Saline (PBS), then stained with the following antibodies
against cell surface receptors: anti-CD14,d anti-CD16,e anti-
CD62L,f anti-CD32e, anti-CD11c,g anti-CCR2,h anti-CCR7h,
anti-CD43h, anti-CX3CR1
h, and anti-CXCR2h (Table 1). A tube
containing unstained cells served as a negative control, and the
appropriate isotype controls (IgG2a PEf, IgG1 FITCf, rabbit poly-
clonale conjugated antibodies) were applied. Single color compen-
sation controls were established at the start of these experiments,
and the data shown here represent multicolor analysis. All
antibodies were directly conjugated to fluorescein isothiocyanate
(FITC), phycoerythrin (PE), or allophycocyanin (APC). The
stained cells were incubated for 20 minutes on a shaker at low-
speed, in the dark, at room temperature, after which the cells were
washed twice with PBS. A FacsCaliberi flow cytometer was used
to perform FACS analysis, and the data were analyzed using the
accompanying CellQuestTM software. Monocytes were gated based
on FSC and SSC (Fig 1a), and gates for determining the percent-
age of monocytes that stained positive for antibody were set using
isotype controls as guidelines.
Total RNA Extraction, Reverse Transcription, and
Quantitative RT-PCR
Sorted monocytes from 7 healthy controls and 7 dogs with
OSA were used for PCR analysis. The RNeasy minikitc was used
to extract total RNA for quantitative RT-PCR (qPCR) from the
sorted monocytes according to the manufacturer’s protocol. We
verified the quality and quantity of the purified RNA using a
Table 1. List of antibodies used for flow cytometry.
Antibodies Clone Isotype Fluorescence labeling
CD14 T €UK4 mIgG2a APC, FITC
CD16 LNK16 mIgG1 PE
CD62L SK11 mIgG2a PE
CD32 AT10 mIgG1 FITC
CD11c BU15 mIgG1 FITC
CCR2 Polyclonal Rabbit FITC
CCR7 Polyclonal Rabbit FITC
CD43 Polyclonal Rabbit FITC
CX3CR1 Polyclonal Rabbit FITC
CXCR2 Polyclonal Rabbit FITC
CD, cluster of differentiation; m, mouse; IgG, immunoglobulin
G; APC, allophycocyanin; FITC, fluorescein isothiocyanate; PE,
phycoerythrin.
1168 Tuohy et al
ab
c
Fig 1. Monocyte surface marker expression is altered in dogs with OSA: Flow cytometry dot plots illustrating cell surface receptor expres-
sion in peripheral blood monocytes from dogs with OSA (n = 18) and healthy controls (n = 13). (a) Representative dot plot showing
monocyte gating using forward and side scatter characteristics. CD14 staining was used to ensure that the majority of the gated monocytes
exhibited positive CD14 cell surface expression. (b) Box-and-whisker plot depicting the % positive monocyte cell surface receptor expres-
sion of the different receptors (CD14, CD16, CD32, CD62L, CCR2, CCR7, CD43, CX3CR1, CXCR2), comparing expression between
healthy controls and dogs with OSA. The median percentages and ranges of positively staining cells for each antibody in healthy controls
are as follows: CD14 (15%, 3–84%), CD16 (9%, 0.5–24%), CD32 (33%, 1–82%), CD62L (31%, 10–75%), CCR2 (58%, 2–94%), CCR7
(36%, 1–90%), CD43 (52%, 2–93%), CX3CR1 (9%, 0.2–87%), and CXCR2 (54%, 2–92%). The median percentages and ranges of posi-
tively staining cells for each antibody in dogs with OSA are as follows: CD14 (29%, 2–82%), CD16 (24%, 3–76%), CD32 (28%, 4–52%),
CD62L (11%, 3–36%), CCR2 (29%, 3–45%), CCR7 (8%, 0.1–41%), CD43 (28%, 3–47%), CX3CR1 (5%, 0.6–70%), and CXCR2 (23%,
0.2–52%). Significant differences are marked with an asterisk (P < .05). Chemokine receptors have significantly decreased expression, and
CD16 expression is significantly increased in monocytes of dogs with OSA. (c) Representative dot plots showing the percentage cell surface
expression of CD14 and CCR2 in monocytes of a healthy control (upper panel) versus an OSA dog (lower panel). There was no significant
difference between CD14 expression in OSA compared to control dogs. A portion of the CD14 positive monocytes in dogs with OSA were
noted to have increased forward scatter, denoting larger cell sizes. CCR2 expression is significantly decreased in dogs with OSA
(P = .0006). Representative dot plots for isotype controls are displayed for each dog.
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NanoDrop 2000c spectrophotometerg, and also used gel elec-
trophoresis to confirm RNA quality (Figure S1a). cDNA was sub-
sequently synthesized in a Techne TC4000j thermal cycler using
the Promega© RT kitk according to manufacturer’s directions. Pri-
mers for qPCR to detect mRNA expression levels of Interleukin-
10 (IL-10), Interleukin-12 (IL-12), Tumor Necrosis Factor-alpha
(TNF-a), and Cyclooxygenase-2 (COX-2) were selected based on
previous reports (Table 2),10,11 and purchased from Integrated
DNA Technologies.l The PerfeCTa SYBR Green FastMix for
iQTM PCR kitm was used for mRNA expression detection, and the
reactions performed with the iCycler iQTM real-time PCR detection
system.n All samples were run in triplicate. The thermal cycling
conditions were as follows: cycle 1 (95.0°C for 8 minutes) 1X,
cycle 2 (95.0°C for 30 seconds, 56.0°C for 20 seconds, 72.0°C for
40 seconds) 40X, cycle 3 (melting curve starting at 60.0°C for
10 seconds, with stepwise increases of 0.5°C for 70X to achieve
95°C), and cycle 4 (hold at 4.0°C). The housekeeping gene, Glycer-
aldehyde-3-Phosphate Dehydrogenase (GAPDH), was used for
normalization of results. The CT value of GAPDH was consistent
across experiments and between animals for all PCR results
reported here (CT = ~21). The PCR product was separated using
agarose gel electrophoresis, the DNA was sequenced by GENE-
WIZ DNA sequencing services, and the sequences were subjected
to alignment searches in the NCBI database to confirm matches
with the gene of interest (Figure S1b). The 2DDCT method was
used to derive the normalized relative mRNA expression level of
the target genes.
Prostaglandin ELISA
Sorted monocytes from 8 healthy controls and 7 dogs with
OSA were used for stimulation experiments—half of these mono-
cytes served as unstimulated controls and incubated for 6 hours at
37°C and 5% CO2. The other half were stimulated with 100 ng/
106 monocytes of lipopolysaccharide (LPSa) and incubated simi-
larly for 6 hours at 37°C and 5% CO2. The resultant supernatants
were collected, stored at 20°C until they were assessed for PGE2
levels using a commercially available ELISA kito according to
manufacturer’s directions.
IL-10, IFN-c, TNF-a Magnetic Bead Panel Assay
Sorted monocytes from 5 healthy controls and 5 dogs with
OSA were used for stimulation experiments as described for the
prostaglandin ELISA. The resultant supernatants were collected,
stored at 20°C until they were assessed for IL-10, IFN-c, and
TNF-a levels using a commercially available canine cytokine mag-
netic bead panel kit (MILLIPLEX MAP)p according to manufac-
turer’s directions. IL-12 was not available as an analyte in the kit,
thus IFN-c levels were analyzed as a surrogate, as IL-12 is known
to induce IFN-c secretion.
Chemotaxis Assay
Sorted monocytes from 14 healthy controls and 5 dogs with
OSA were used for migration assays. Monocyte migration was
assessed using a NeuroProbe ChemoTxq 96-well disposable cell
migration system with 8 lm polycarbonate framed filters. Sorted
monocytes were resuspended in 106/mL of cell culture media,
labeled with 1 lg calcein-AMr /106 monocytes, and the cells incu-
bated for 30 minutes in the dark at room temperature. Following
incubation, the cells were resuspended at 106/mL in Dulbecco’s
Modified Eagle Medium (DMEMs ). Twenty-five lL of the cell
suspension were deposited on each filter. The lower chamber, ie,
the 96-well plate, contained the following: 100% heat-inactivated
fetal bovine serum (FBSg), 100 ng/mL monocyte chemoattractant
protein-1 (MCP-1t ), 100 nM N-Formyl-L-Methionyl-L-Leucyl-L-
Phenylalanine (fMLPa), 100 ng/mL CCL19t as positive
chemoattractants, and PBS as a negative control. The positive
chemoattractants were either placed individually in separate wells,
or combined together in a single well. For total cell counts, 25 lL
of cells was placed directly into the lower well to quantify maximal
fluorescence. The plate was incubated for 4 hours at 37°C, after
which the nonmigrated cells on top of the filters were gently wiped
off using a cell scraper. Cellular fluorescence in the bottom wells
was quantified using a fMax fluorescence microplate readeru at
485 and 538 nm wavelength, and the corresponding SoftMax Pro
software. Filter fluorescence was also quantified to confirm that
cells were not adherent to the underside of the filter. Degree of
migration was calculated as a percentage of migrated cells out of
the known cell numbers placed in bottom wells. Cell migration
was expressed as a migration index, calculated by dividing directed
cell chemotaxis (cells migrating in response to a chemokine, quan-
tified by degree of fluorescence) by random cell chemotaxis (cells
migrating in response to media alone, quantified by degree of fluo-
rescence). Each sample was assayed in triplicate.
Statistical Analyses
Statistical analyses were performed to compare monocyte cell
surface receptor expression levels between groups using the non-
parametric Mann-Whitney U-test because of the non-normal dis-
tribution of the data. Comparison of relative mRNA expression of
each gene and of PGE2 levels between groups were analyzed with
the Mann-Whitney U-test. All statistical tests were carried out as
2-sided tests, and a P-value of <.05 was considered significant.
Comparison of peripheral blood monocyte counts between dogs
with OSA and healthy controls was performed using a 2-tailed
T-Test. Pearson’s correlation coefficient was used to determine the
strength and direction of a possible linear relationship between
monocyte surface receptors and peripheral blood monocyte counts.
Two-way ANOVAs and least-squares means were used to test for
differences in monocyte surface receptors because of status and
monocyte counts (high versus low). To analyze the chemotaxis
data, one-way ANOVAs were run and means were compared
using Welch’s adjustment for heterogeneous variation. Kaplan-
Meier survival analysis was used to compare survival between
groups, with proportional hazards regression analysis to test the
effect of chemokine receptor expression on survival. Survival was
calculated as the number of days from diagnosis of disease to
death attributed to disease, or last follow-up if the patient was still
Table 2. Quantitative RT-PCR primers to detect
mRNA expression levels of proinflammatory and anti-
inflammatory cytokines, and COX-2.
Target (50–30)
Position
(bp)
IL-10 (F) GCGACGCTGTCACCGATT 379–396
IL-10 (R) CTGGAGCTTACTAAATGCGCTCTT 460–437
IL-12 (F) TGGCTGCTATTCACAAGCTCAAGT 638–661
IL-12(R) TGGTTTGATGATGTCTCTGATGAAG 708–684
TNF-a
(F)
AGCCAGTAGCTCATGTTGTAGCAA 759–781
TNF-a
(R)
GGCACTATCAGCTGGTTGTCTGT 358–380
COX-2
(F)
CTGTTCCCACCCATGTCAA –
COX-2
(R)
GCAGTTTTCGCCGTAGAATC –
F, forward primer; R, reverse primer.
1170 Tuohy et al
alive. A dog was determined to have died of disease if metastasis
or local tumor recurrence was the cause, and dogs with an
unknown cause of death were presumed to be dead because of dis-
ease. Dogs were censored from the analysis if they were still alive
at last follow-up. All analyses were performed using SAS software
(Version 9.4, Cary, NC). All statistical analyses were performed in
consultation with the NCSU Biostatistics consulting group (Dr. E.
Griffith).
Results
Study Population
The mean (SD) age at time of OSA diagnosis was
8.7 (2.1) years. All dogs with OSA were purebred,
with the most common pure breeds being Labrador
Retriever (5 [28%]), Rottweiler (3 [17%]), Great Dane
(3 [17%]), and Golden Retriever (2 [11%]). There
were 8 (44%) spayed females, and 10 (56%) castrated
males.
Monocyte Surface Receptor Expression
The primary flow cytometry canine monocyte gates
were based on typical forward and side scatter charac-
teristics. Once that forward versus side light scatter gate
was established, we ensured that greater than 98%
of the CD14+ cells were found within this gate. As
CD14 expression on peripheral blood monocytes varies
greatly, this ensured that we included the CD14l,o
monocytes for surface receptor analysis (Fig 1a). Mono-
cytes exhibited positive surface expression of CD14,
CD16, CD32, CD62L, CCR2, CCR7, CD43, CX3CR1,
CXCR2, with low levels of CD11c. Irrelevant isotype
controls were used for each experiment—the isotype
control binding of monocytes was <5%. The median
percentages and ranges of positively staining cells for
each antibody are listed in the legend accompanying
Fig 1b. Comparison of monocyte surface receptors
between untreated dogs with OSA and healthy controls
revealed a significant decrease in surface receptor
expression of CD62L (P < .00001), CCR2 (P = .0006),
CCR7 (P = .0004), CD43 (P = .008), CX3CR1
(P = .002), CXCR2 (P = .0007) in dogs with OSA, and
a significant increase in CD16 expression in dogs with
OSA (P = .005) (Fig 1b). Fig 1c depicts representative
dot plots with the percentage of cell surface receptor
expression in monocytes of a healthy control versus an
OSA dog.
A peripheral blood monocyte count of >400 cells/lL
has been significantly associated with decreased disease-
free interval in dogs with OSA.12 Others have reported
associations between peripheral blood monocyte counts
and outcomes in humans with OSA.13 Hence, we evalu-
ated the flow cytometry data in conjunction with
peripheral blood monocyte counts, using 400 cells/lL
as a differentiation point between high and low mono-
cyte counts according to previously reported findings.12
There was no significant difference in the peripheral
blood monocyte counts of dogs with OSA
(mean = 514.7 cells/lL, SD = 377.9 cells/lL) compared
to healthy controls (mean = 331.9 cells/lL, SD =
192.6 cells/lL; P = .16). Comparison of receptor expres-
sion between dogs with high (>400 cells/lL) versus low
(<400 cells/lL) monocyte counts revealed a dichotomy
of CD14, CD16 expression in dogs with OSA— CD14
expression is high (P = .01) and CD16 expression is low
(P = .02) when monocyte counts are high (Table 3).
Least-squares means from the 2-way ANOVA compar-
ing relationships between monocyte counts and receptor
expression are shown in Table S1.
In healthy controls, there were strong significant posi-
tive correlations between chemokine receptors, whereas
in dogs with OSA, there were fewer and less robust sig-
nificant positive correlations between chemokine recep-
tors (Fig 2). The Pearson’s correlation values with
corresponding P-values are represented in Table S2.
Relative mRNA Expression of Monocyte IL-10, IL-
12, TNF-a, and COX-2
TNFa, IL-10, and IL-12 are inflammatory mediators
secreted by monocytes and macrophages, and differen-
tial levels of TNFa, IL-10, and IL-12 secretion have
been described for the various human monocyte sub-
sets,14,15 reflecting subset-specific functional differences.
COX-2 expression in monocytes reflects a proinflamma-
tory state.16–18 We compared relative mRNA expression
of IL-10, IL-12, TNFa, and COX-2 in dogs with OSA
versus healthy controls to discern potential variation in
cytokine secretion that might reflect functional differ-
ences. mRNA expression analysis of monocytes from
untreated dogs with OSA and healthy controls revealed
no significant differences in relative mRNA expression
levels of IL-10 (P = .44), IL-12 (P = .41), and TNF-a
(P = .14) between the 2 groups. The relative mRNA
expression of COX-2 was decreased in dogs with OSA
compared to healthy controls, but the difference was
not significant (P = .08).
Evaluation of IL-10, IFN-c, TNF-a, and prostaglandin
E2 secretion from monocytes
As mRNA levels might not consistently correspond
with protein secretion, we analyzed monocyte secretion
of the cytokines IL-10, IFN-c, TNF-a, and PGE2. Simi-
lar to our mRNA evaluation, we compared cytokine
secretion from monocytes of dogs with OSA versus
healthy controls to assess for functional differences.
Secretion of cytokines such as TNF-a, IL-10, IFN-c, and
PGE2 has been noted to differ between human monocyte
subsets, and can be affected by disease.15,17 PGE2 ELISA
and the MILLIPLEX assay revealed increased PGE2
levels (P = .04) and increased TNF-a levels (P = .02),
respectively in supernatants of cultured monocytes stimu-
lated with LPS of untreated dogs with OSA compared to
normal controls (Fig 3a, b). The median concentrations
and ranges of PGE2 concentrations were 347.36 pg/mL,
103.4–1268.5 pg/mL for dogs with OSA, and 136.23 pg/
mL, 69.93–542.6 pg/mL for healthy controls. The
median concentrations and ranges of TNF-a levels were
934.7 pg/mL, 644.3–2709 pg/mL for dogs with OSA,
and 267.2 pg/mL, 70.4–670.4 pg/mL for healthy
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controls. Levels of IL-10 and IFN-c were low to unde-
tectable in both groups.
Monocyte Chemotaxis
The results of our phenotypic analysis of monocytes
between dogs with OSA and healthy controls revealed
marked decreases in chemokine receptor expression in
dogs with OSA (Fig 1b,c). Therefore, we asked whether
monocyte chemotaxis might be altered by OSA. As
described in our methods, monocytes from OSA and
healthy dogs were assessed by the NeuroProbe Che-
moTx cell migration system. Comparison of monocyte
chemotaxis between dogs with OSA and healthy con-
trols revealed significantly decreased chemotaxis in dogs
with OSA when CCL19 (P = .018), and when a mixture
of all 4 chemoattractants (P = .018) was used (Fig 4).
With CCL2 or fMLP as chemoattractants, there was
also decreased monocyte chemotaxis in dogs with OSA
compared to healthy controls, but the difference did not
reach significance (CCL2 P = .067; fMLP P = .067).
Survival Analysis
As a peripheral monocyte count of >400 cells/lL has
been significantly associated with decreased disease-free
interval in dogs with OSA,12 we performed a Kaplan-
Meier survival analysis comparing dogs with OSA with
high or low monocyte counts, using 400 cells/lL as a
cut-off point. One dog died of unknown cause, and was
assumed to have died from OSA. We did not find a sta-
tistically significant difference in median survival
between the 2 groups (P = .15, Fig 5). Our regression
analysis revealed that increasing percentages of CCR2
expression on peripheral monocytes was significantly
associated with increasing survival in dogs with OSA
(P < .0001).
Discussion
The goal of this study was to determine phenotypic
and functional differences between peripheral blood
monocytes from untreated dogs with OSA versus
healthy age-matched controls. Our hypothesis was that
evasion of the immune response by OSA is due in part
to down-regulation of monocyte chemokine receptor
expression and migratory function, and suppression of
host immune responses. We demonstrated a significant
decrease in monocyte chemokine receptors, increased
PGE2 and TNF-a secretion by monocytes, and
decreased monocyte chemotaxis in dogs with OSA.
Monocytes display a variety of cell surface receptors,
including leukocyte chemokine receptors. CD62L, also
known as L-selectin, is a cell adhesion molecule present
on immune cells such as monocytes, lymphocytes, and
NK cells. CD62L mediates the trafficking of these cells
to sites of inflammation and peripheral lymphoid tissue
by binding to glycoproteins.19,20 CCR2, a chemokine
receptor for MCP-1, is especially prominent in mediat-
ing monocyte migration.21 Similarly, CCR7 regulates
migration of leukocytes to secondary lymphoid organs
via binding of its ligands CCL19 and CCL21.20 CD43
can be found on a variety of immune cells including
lymphocytes, granulocytes, monocytes, macrophages,
and NK cells, and it plays a role in cell adhesion and
migration.22,23 CX3CR1, and CXCR2, both G protein-
coupled chemokine receptors, mediate lymphocyte,
monocyte and granulocyte migration.20 There are few
reports describing the effect of OSA on monocyte
surface receptor expression in dogs. For example,
down-regulation of MHC class II and CD80 in canine
myeloid cells when exposed to tumor cell lines including
OSA in vitro has been observed.24 In humans, the
prevalence of an immunosuppressive phenotype in
peripheral blood monocytes of OSA patients has been
observed.13 However, to the authors’ knowledge, there
are no reports evaluating phenotypic changes in mono-
cytes of clinical dogs with OSA.
We assessed the expression of monocyte surface
receptors using flow cytometry, and demonstrated that
peripheral blood monocytes from dogs with OSA exhib-
ited significantly decreased chemokine receptor expres-
sion, namely of CD62L, CCR2, CCR7, CD43,
CX3CR1, and CXCR2. This pronounced down-regula-
tion of monocyte chemokine receptors of dogs with
OSA suggests a peripheral sequestration of monocytes,
inhibited from migrating to sites of need such as the
primary tumor or metastatic lesions. Two of the chemo-
kine receptors, CCR2 and CXCR2, had significantly
higher expression on monocytes of healthy controls
with low monocyte counts compared to monocytes of
dogs with OSA that had high or low monocyte counts.
This supports our theory that the decreased expression
of chemokine receptors in dogs with OSA reflects a
peripheral sequestration. There was no difference in the
mean peripheral monocyte counts between dogs with
Table 3. Comparison of receptor expression between dogs with high (>400 cells/lL, n = 11) versus low (<400 cells/lL,
n = 17) monocyte counts. In dogs with OSA, when monocyte counts are high, there is a dichotomy of CD14, CD16
expression—CD14 is high (P = .01) and CD16 is low (P = .02).
Chemokine receptor Monocyte counts
Control Dogs Dogs with OSA
Median (% expression) P-value Median (% expression) P-value
CD14 High 11.9 .90 37.5 .01
Low 7.7 13.9
CD16 High 2.8 .15 5.7 .02
Low 11.3 37.3
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Fig 2. Chemokine receptor correlation is disrupted in OSA: Correlations between chemokine receptors in healthy controls (n = 13) versus
dogs with OSA (n = 18). Representative dot plots displaying correlations between pairs of monocyte chemokine receptors CD43 and
CCR2 (n = 13 for healthy controls; n = 14 for dogs with OSA), CXCR2 and CCR2 (n = 13 for control dogs; n = 15 for dogs with OSA),
CXCR2 and CD43 (n = 13 for healthy controls; n = 14 for dogs with OSA). There are strong positive correlations between chemokine
receptors in healthy controls, compared to the less robust correlations between receptors in dogs with OSA.
Canine Osteosarcoma and Monocytes 1173
OSA and healthy controls, which could indicate that
this parameter is not as sensitive for detecting a periph-
eral sequestration compared to analyzing the relation-
ship between chemokine receptors and monocyte counts
in both groups of dogs. Alternatively, the lack of differ-
ence in mean monocyte counts could also refute our
theory of peripheral monocyte sequestration in OSA.
We found a strong positive correlation between expres-
sion of chemokine receptors in healthy controls,
whereas the correlation was less robust in dogs with
OSA, suggesting a disturbance in the regulation of these
chemokine receptors.
A retrospective study of dogs with OSA found that
dogs with peripheral monocyte counts above 400 cells/lL
had a significantly shorter disease-free interval.12 Simi-
larly, in human OSA patients, a low peripheral lympho-
cyte-to-monocyte ratio (≤3.43) was associated with
poorer prognosis for survival and disease-free interval.25
One possible explanation is that higher monocyte
counts reflect a peripheral sequestration of monocytes
in dogs that had more rapid tumor progression, and
our findings of suppressed expression of multiple mono-
cyte chemokine receptors in dogs with OSA suggest
such an association. We did not detect a significant
overall difference in peripheral monocyte counts of dogs
with OSA versus healthy controls in our study popula-
tion. Our Kaplan-Meier survival analysis comparing
dogs with OSA with high (>400 cells/lL) versus low
(<400 cells/lL) monocyte counts did not reveal signifi-
cant differences in survival between groups. However,
we did find that increasing percentages of CCR2 expres-
sion on monocytes of dogs with OSA was significantly
associated with increasing survival, which, in conjunc-
tion with our chemotaxis data, suggests that suppres-
sion of chemokine receptors and chemotaxis is a form
of tumor-mediated monocyte dysfunction.
Additionally, we found that dogs with OSA with a
peripheral monocyte count of >400 cells/lL exhibited a
dichotomy of CD14, CD16 expression on monocytes—
CD14 expression was high and CD16 expression was
low, when compared to dogs with monocyte counts
<400 cells/lL. Human monocytes have been classified
into subsets, with different phenotypes and functions.
Earlier classification schemes split human monocytes
into CD14highCD16- “inflammatory, classical” and
CD14lowCD16+ “resident, nonclassical” monocytes.26,27
Recent studies have shown that the CD16+ monocytes
can be further characterized into intermediate and non-
classical subsets, with the intermediate subset expressing
higher CD14 and lower CD16 levels, and the nonclassi-
cal subset conversely expressing lower CD14 and higher
CD16 levels.15 The function of these monocyte subsets
has not been fully defined, but the intermediate subset
appears to produce proinflammatory cytokines such as
TNF-a, IL-1b, IL-6, express high levels of MHC II
antigen processing and presentation genes, and are
potent stimulators of T cells.15 There are no corre-
sponding studies differentiating canine monocytes into
subsets. Based upon human classification, our data sug-
gest that there is an increase in intermediate monocytes
in dogs with OSA with monocyte counts >400 cells/lL.
Potentially, these intermediate monocytes, with their
proinflammatory and immunostimulatory capacity, are
effective antitumor monocytes that are sequestered in
the periphery in OSA.
Monocyte migration can reportedly be affected by
neoplasia. Peripheral monocyte migration is inhibited
by lactate concentrations common in tumor microenvi-
ronments, and this loss of migratory ability is not
because of a reduction in cell viability.28 Chemokine
Fig 3. Monocyte PGE2 and TNF-a secretion are increased in
OSA: Box-and-whisker plots displaying the levels of (a) PGE2 (pg/
mL) in monocyte culture supernatants of healthy controls (n = 8)
versus dogs with OSA (n = 7), and (b) TNF-a (pg/mL) in mono-
cyte culture supernatants of healthy controls (n = 5) versus dogs
with OSA (n = 5). Monocytes from dogs with OSA secreted signif-
icantly higher levels of PGE2 (P = .04) and TNF-a (P = .02) com-
pared to healthy control monocytes.
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receptors such as CCR5 are down-regulated in mono-
cytes and macrophages in human patients with head
and neck squamous cell carcinoma, leading to dysregu-
lation of chemotactic receptor-ligand signaling and
decreased monocyte/macrophage migratory ability.29
Based on findings by other investigators and our
demonstration of profound down-regulation of
monocyte chemokine receptors in dogs with OSA, we
hypothesized that OSA inhibits monocyte chemotaxis as
an immunosuppressive strategy. Using an in vitro
migration assay, we demonstrated decreased monocyte
chemotaxis in dogs with OSA compared to healthy con-
trols. This difference was significant when CCL19 was
used as a chemoattractant, and when supraphysiologic
combinations of chemoattractants were used—a combi-
nation of FBS, CCL2, CCL19, and fMLP. CCL19 is a
ligand for the chemokine receptor CCR7, and is a
known monocyte chemoattractant.30 There was also
decreased monocyte migration in dogs with OSA when
other known chemokines such as CCL2 or fMLP were
used, and even though the differences were not signifi-
cant, the proximity of the P-value (.067) to significance
(.05) suggests that use of these chemokines deserves fur-
ther evaluation. CCL2 is also known as monocyte
chemotactic protein, binds CCR2, and together with
fMLP, which binds to G protein-coupled receptors, is
used as chemoattractants for monocytes. The significant
down-regulation of CCR2 and CCR7 on monocytes of
dogs with OSA demonstrated by our flow cytometry
data supports the observation that monocyte migration
is decreased in dogs with OSA. The primary disadvan-
tage of our method for assessing migration was the high
level of random migration observed, potentially because
of excessive stimulation of monocytes by the cell sorting
process. As a result, we included supraphysiologic com-
binations of chemoattractants to counter this potential
issue.
Fig 4. Monocyte chemotaxis is decreased in OSA: Box-and-whisker plot comparing the mean levels of random: directed monocyte migra-
tion for the various chemokines used, either alone or in combination (CCL2, CCL19, FBS, fMLP) between healthy controls (n = 14) and
dogs with OSA (n = 5). Monocyte migration is significantly reduced in dogs with OSA when CCL19 (P = .018) or a combination of
chemokines (P = .018) was used as chemoattractants. Decreased migration in dogs with OSA was also observed with CCL2 or fMLP as
chemoattractants, but the difference did not reach significance (CCL2 P = .067; fMLP P = .067).
Fig 5. Peripheral blood monocyte counts do not affect survival in
OSA: Kaplan-Meier analysis of survival times comparing dogs
with OSA with high (>400 cells/lL; n = 8) versus low (<400 cells/lL;
n = 9) monocyte counts did not reveal any significant difference
between the 2 groups (P = .15). Median survival of dogs with high
monocyte counts was 247.5 days, versus 337 days in dogs with
low monocyte counts.
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There could be a multi-faceted explanation for the
down-regulation of monocyte chemokine receptors in
dogs with OSA. Similar to our findings, the loss of
CX3CR1 expression in human monocytes increased
glioma growth.31 However, in contrast to our observa-
tions, this tumor-promoting effect is not because of loss
of migratory capability. In fact, the absence of CX3CR1
was associated with an increase in monocyte infiltration
into the tumor microenvironment, where the monocytes
were theorized to differentiate into tumor-associated
macrophages for promotion of tumor growth. Evaluation
of the relationship between monocyte chemokine receptor
expression and the infiltration of monocytes/macro-
phages in the tumor microenvironment in OSA is needed
to explore whether this phenomenon occurs in dogs.
The higher PGE2 levels that we observed in monocyte
culture supernatants of dogs with OSA are consistent
with our hypothesis that OSA suppresses monocyte
chemotaxis and the host immune response. PGE2 is a
main metabolite resulting from the conversion of
arachidonic acid by cyclooxygenases (COX-1 and COX-
2), and increased levels of COX-2 and PGE2 have been
observed in various tumors.32–35 PGE2 secretion from
human carcinoma cell lines inhibits monocyte chemo-
taxis by down-regulating cell surface expression of che-
mokine and adhesion receptors CCR5 and Mac-1,
respectively.36 Our finding of increased PGE2 secretion
from monocytes of dogs with OSA correlates with our
observation that monocyte chemotaxis is inhibited
in OSA. Increased PGE2 levels have been shown to
effect global immunosuppression, contributing to
immunopathology in many cancers.37 For example,
PGE2 disables the innate immune response by inhibiting
neutrophils, monocytes and macrophages, and disrupts
the cross-talk between dendritic cells and T cells that is
essential for activation of the adaptive immune
response. PGE2 also skews T helper cells toward a type
2 pro-tumorigenic instead of a type 1 antitumor
response, and promotes the accumulation of T regula-
tory and myeloid-derived suppressor cells, which can be
utilized by the tumor to suppress an effective antitumor
response.37 A recent study in human OSA showed inhi-
bition of human OSA cells by decreasing PGE2 levels
via microRNA modulation, demonstrating the role of
PGE2 in tumor promotion.
38 Specifically in OSA of
dogs, PGE2 is increased in both canine OSA cell lines
and in naturally occurring tumors,39 COX-2, microso-
mal PGE2 synthase-1, and PGE2 receptor are demon-
strated to be increased in OSA lesions using
immunohistochemistry staining,40 and OSA cells from
dogs secrete PGE2.
41 Our findings of increased PGE2 in
dogs with OSA are in accordance with these previous
reports, and emphasize the ability of PGE2 to induce
immunopathology in OSA.
We did not find significant differences in relative
mRNA expression of IL-10, IL-12, TNF-a, and COX-2
in monocytes from OSA compared to healthy dogs.
There was a decreasing trend in COX-2 expression in
dogs with OSA, but the difference from healthy controls
was not significant. This is contrary to what we
expected, given the higher PGE2 secretion from
monocytes of dogs with OSA, and the overexpression
of COX-2 that has been reported in OSA of dogs.40,42
Potentially, there might be other enzymes such as
microsomal PGE2 synthase-1 that could be concurrently
influencing the level of PGE2 secretion. However, as the
difference in COX-2 expression between OSA and
healthy dogs was not statistically significant, whether
COX-2 expression in monocytes of dogs with OSA is
truly decreased needs to be further evaluated, as other
influences such as miRNA activity can affect mRNA
transcription. Because of potential disparities between
mRNA and protein expression, we evaluated monocyte
secretion of TNF-a, IFN-c, and IL-10, using IFN-c as
representative of IL-12 activity. There were low to
undetectable levels of IFN-c and IL-10 from both
groups, and higher levels of TNF-a secreted from
monocytes of dogs with OSA. This was an unexpected
finding, as TNF-a is a proinflammatory cytokine. How-
ever, TNF-a induces a number of other changes, partic-
ularly in the context of the tumor microenvironment.
TNF-a induces the up-regulation of IL-34 expression in
OSA cell lines, and IL-34 has been associated with pro-
gression of disease and promotion of angiogenesis in
OSA.43 TNF-a has also been shown to increase the pro-
duction of PGE2 as a mechanism for effecting bone
resorption.44 Potentially, the increase in TNF-a in
monocytes of dogs with OSA reflects tumor-driven
mechanisms for OSA promotion rather than induction
of a proinflammatory monocyte response. Other
immunomodulatory cytokines such as TGF-b are uti-
lized by OSA for tumor promotion. TGF-b, generally
known to dampen immune responses and promote
tumor growth, is secreted by OSA cells from dogs,6 and
has also been implicated in the pathogenesis of human
OSA.45 Collectively, these findings indicate a complex
microenvironment that promotes immune dysfunction
and tumor growth.
One potential limitation of this study is the use of
clinical dogs and random source healthy controls,
instead of purpose-bred dogs which provide a geneti-
cally uniform study population. However, one strong
advantage of using nonpurpose-bred dogs is the genetic
diversity that accurately reflects that of the general pet
population. This diversity, together with the exposure
to shared environmental variables with humans, con-
tributes to the unique canine model of spontaneously
occurring OSA that bears striking similarities to the
human disease. Such a model is extremely valuable for
studying the disease to improve outcomes for both
humans and dogs.
In conclusion, this study demonstrated that monocyte
chemokine receptors are markedly down-regulated in
dogs with OSA compared to healthy controls, and
monocytes from dogs with OSA exhibit decreased
chemotactic capacity and secrete higher levels of PGE2
and TNF-a. Our findings strongly suggest that OSA in
dogs evades the immune system by suppressing chemo-
kine receptor expression and increasing PGE2 secretion
in monocytes, thus inhibiting their migration, leading to
sequestration in the periphery. Increased PGE2 levels
could also promote immunosuppression, as PGE2 can
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exert a multitude of immunopathologic effects such as
interfering with lymphocyte proliferation and the antitu-
mor cytotoxicity of T cells, inhibit NK cell, dendritic
cell, neutrophil, monocyte and macrophage effector
functions. Increased TNF-a secretion could be a tumor-
promoting mechanism through manipulation of the
tumor microenvironment and elevating PGE2 produc-
tion. Understanding the mechanisms by which OSA
causes dysregulation of the immune response will pro-
vide insight into developing novel immunotherapeutics
to reverse tumor-induced immunopathology and reduce
metastatic disease in OSA.
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l Integrated DNA Technologies, IO (Primers for PCR)
m Quanta Biosciences, Gaithersburg, MD (PCR SYBR Green kit)
n Bio-Rad, Hercules, CA (iCycler)
o Cayman Chemical, Ann Arbor, MI (PGE2 ELISA kit#514010)
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PLEX MAP kit)
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r AnaSpec Inc., Fremont, CA (Calcein)
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